Last updated: November 13, 2026
Gadobenate dimeglumine, marketed primarily as MultiHance by Bracco, is an established gadolinium-based contrast agent for magnetic resonance imaging. Its commercial profile is mature rather than growth-driven: revenue depends on MRI procedure volumes, hospital purchasing, supply reliability, and competition from lower-cost generic and branded gadolinium agents. Bracco does not publicly disclose MultiHance revenue as a separate product line, so the drug’s financial trajectory must be assessed through company reporting, regulatory status, market-share indicators, and contrast-media industry trends.
What is gadobenate dimeglumine and how is it used?
Gadobenate dimeglumine is a gadolinium-based extracellular contrast agent used to enhance MRI images. The product is also known as gadobenate or Gd-BOPTA. MultiHance is supplied as an injectable solution and is used in adults for central nervous system MRI and magnetic resonance angiography, as well as for focal liver lesion imaging. The FDA approved MultiHance in 2004 for central nervous system imaging and later expanded its U.S. indication to include liver imaging.[1]
Gadobenate has higher T1 relaxivity than several conventional extracellular gadolinium agents. This property can support image enhancement at lower gadolinium concentrations in selected protocols. Its market positioning has therefore relied on diagnostic performance, established radiology familiarity, and liver-imaging utility rather than a novel delivery technology.
| Attribute |
Gadobenate dimeglumine |
| Brand |
MultiHance |
| Primary manufacturer |
Bracco |
| Active substance |
Gadobenate dimeglumine |
| Drug class |
Gadolinium-based MRI contrast agent |
| Administration |
Intravenous injection |
| Main imaging uses |
CNS, MRA, liver |
| U.S. original approval |
2004 |
| Regulatory category |
Small-molecule contrast agent |
| Commercial maturity |
Mature branded product |
| Biosimilar exposure |
None |
What is the FDA and Orange Book status of MultiHance?
MultiHance is an FDA-approved prescription drug under Bracco’s New Drug Application. The product is listed in FDA drug databases as gadobenate dimeglumine injection. Its regulatory value comes from an approved product, manufacturing controls, established safety data, and label-specific clinical use.
The product is not a biologic and does not generate biosimilar competition. Any follow-on product would generally compete through an abbreviated new drug application or another applicable small-molecule pathway, not through the biosimilar framework.
The FDA’s Orange Book is the primary source for determining current patent and exclusivity listings. For an older contrast agent such as MultiHance, commercial protection is more likely to depend on manufacturing, supply, quality, customer contracts, and brand recognition than on unexpired core composition patents. Patent listings and regulatory exclusivity can change, and the current Orange Book entry controls the operative U.S. status.[2]
| Regulatory issue |
Market implication |
| Original approval in 2004 |
Long commercial history and extensive clinical use |
| Small-molecule status |
Generic pathway available in principle |
| No biologic designation |
No biosimilar exclusivity framework |
| Mature FDA label |
Limited room for broad new-chemical-entity exclusivity |
| Orange Book relevance |
Determines listed patents and any associated generic certification risk |
When does gadobenate dimeglumine lose exclusivity?
The principal U.S. regulatory exclusivity periods associated with the original approval have expired. The 2004 approval is outside the five-year new chemical entity exclusivity period, and the product’s later label expansions are also outside the normal three-year exclusivity window associated with qualifying clinical investigations.
No current commercial thesis should rely on remaining NCE exclusivity for gadobenate. The relevant question is whether unexpired patents, regulatory barriers, or manufacturing complexity delay generic entry.
A practical exclusivity timeline is:
| Milestone |
Timing |
Commercial effect |
| Initial U.S. approval |
2004 |
Launch of MultiHance in the United States |
| CNS imaging approval |
2004 |
Establishes initial U.S. commercial base |
| Liver imaging expansion |
2013 |
Broadens addressable MRI demand |
| NCE exclusivity |
Approximately 2004-2009 |
Expired |
| Standard post-approval exclusivity for later clinical supplements |
Product-specific |
Not a current primary barrier |
| Current competitive protection |
Present |
Brand, manufacturing, supply, quality, and contracting advantages |
The absence of meaningful regulatory exclusivity does not guarantee immediate generic substitution. Injectable contrast media require validated sterile manufacturing, reliable supply, regulatory filings, and hospital or group-purchasing adoption. These requirements can slow entry even when the legal patent barrier is limited.
What patents protect gadobenate dimeglumine?
The historic patent estate for gadobenate included composition, chelate chemistry, pharmaceutical formulations, and imaging applications. The key commercial patent question is whether any listed or enforceable U.S. patent remains capable of blocking an ANDA launch.
Gadobenate is a mature contrast agent. Core composition protection associated with the active chelate would generally be expected to have expired or to be close to expiration, depending on the specific patent family and patent-term adjustments. Later patents could have covered formulations, concentrations, manufacturing processes, or methods of imaging, but those rights must be evaluated patent by patent.
What formulations are protected by gadobenate patents?
Potentially relevant formulation claims can include:
- Aqueous injectable compositions containing gadobenate dimeglumine.
- Defined gadolinium concentrations.
- pH ranges and stabilizing excipients.
- Sterile manufacturing and container systems.
- Specific dosing or imaging protocols.
- Methods for enhancing liver or CNS MRI.
Formulation patents often have narrower practical scope than composition patents. They may remain enforceable after the original compound patent expires, but their value depends on whether a generic entrant can design around the claims while meeting FDA quality and labeling requirements.
Are there Paragraph IV challenges to MultiHance?
Publicly visible market information does not establish a major, active Paragraph IV litigation campaign comparable to the patent disputes surrounding high-revenue oncology, immunology, or diabetes products. The absence of prominent litigation is consistent with a mature contrast agent whose revenue opportunity may not justify aggressive patent litigation costs.
A generic applicant could challenge listed patents through an ANDA Paragraph IV certification. A Paragraph IV certification would not itself prove that a launch is imminent. The commercial impact would depend on the specific patents, the filing date, any 30-month stay, settlement terms, and whether the generic applicant receives tentative or final approval.
How large is the gadobenate dimeglumine market?
Gadobenate is part of the global MRI contrast-media market, which includes linear and macrocyclic gadolinium agents. Public market-research estimates vary because vendors define the market differently and do not consistently separate individual products. Product-level revenue for MultiHance is not reported by Bracco in its public financial disclosures.
The market is shaped by five factors:
- MRI procedure growth.
- Hospital and imaging-center purchasing.
- Contrast-agent price competition.
- Gadolinium safety preferences.
- Supply and manufacturing reliability.
MRI utilization has continued to benefit from population aging, oncology imaging, neurologic disease diagnosis, and expanded outpatient imaging. Growth in procedure volume can support gadobenate demand even when unit pricing declines.
Price pressure is stronger in mature hospital markets. Group purchasing organizations and integrated delivery networks often evaluate contrast agents through total acquisition cost, supply guarantees, injector compatibility, clinical familiarity, and formulary standardization.
How does gadobenate compare with competing MRI contrast agents?
Gadobenate competes with both branded and generic products. The most relevant alternatives include gadobutrol, gadoterate meglumine, gadoteridol, gadopentetate dimeglumine, gadodiamide, and gadoversetamide, although the competitive set differs by country.
| Product |
Active agent |
Competitive position |
| MultiHance |
Gadobenate dimeglumine |
Higher-relaxivity agent with liver and CNS use |
| Gadavist/Gadavist |
Gadobutrol |
Macrocyclic, high-concentration agent |
| Dotarem |
Gadoterate meglumine |
Macrocyclic agent with broad hospital use |
| ProHance |
Gadoteridol |
Macrocyclic agent with established CNS use |
| Magnevist |
Gadopentetate dimeglumine |
Older linear agent with declining strategic position |
| Omniscan |
Gadodiamide |
Older linear agent with safety and market-share pressure |
| Optimark |
Gadoversetamide |
Older linear agent with limited commercial relevance |
The market has shifted toward macrocyclic agents because of concerns about gadolinium retention and nephrogenic systemic fibrosis associated with certain linear agents. The European Medicines Agency restricted or suspended several linear agents for particular uses, while the FDA required class labeling concerning gadolinium retention.[3][4]
Gadobenate is a linear ionic agent. It has not been positioned in the same way as the highest-risk nonionic linear agents, but it competes in a market where many buyers increasingly prefer macrocyclic products. That preference can constrain long-term share and pricing.
What is the financial trajectory for gadobenate dimeglumine?
MultiHance is likely a mature, cash-generative product rather than a high-growth asset. Its financial trajectory has four phases:
| Period |
Financial profile |
| 2004-2012 |
Expansion through CNS and broader MRI adoption |
| 2013-2017 |
Benefit from liver-imaging label expansion |
| 2018-2021 |
Pressure from gadolinium safety concerns and pandemic-related imaging disruption |
| 2022 onward |
Recovery in MRI volumes, with ongoing pricing and mix pressure |
Bracco is privately held and does not provide a public, product-level revenue series for MultiHance. The company reports at the group level, which limits direct calculation of product revenue, operating margin, or year-over-year sales growth.[5]
The strongest positive financial drivers are:
- Higher MRI procedure volumes.
- Continued use in liver lesion imaging.
- Stable radiologist preference.
- Manufacturing reliability during contrast shortages.
- Retention in hospital formularies.
- Premium pricing based on image quality or workflow familiarity.
The principal negative drivers are:
- Macrocyclic-agent substitution.
- Generic or authorized-generic entry.
- Hospital tendering and price reductions.
- Declining use of older linear agents.
- Product-specific supply interruptions.
- Greater scrutiny of gadolinium exposure.
What revenue exposure does Bracco have?
MultiHance is strategically relevant to Bracco’s contrast-media portfolio, but public filings do not identify the product’s share of company revenue. Bracco’s broader business includes diagnostic imaging products such as CT and X-ray contrast media, MRI agents, and related imaging technologies. This diversification reduces the company’s financial dependence on any single MRI product.
The product’s revenue exposure is therefore more important for franchise economics than for Bracco’s consolidated financial survival. A rapid decline in MultiHance sales would affect the MRI portfolio, but it would not necessarily create a material group-level impairment without evidence of a large concentration or major manufacturing liability.
What generic launch risks exist for gadobenate?
Generic entry risk is real but probably gradual. The main variables are:
| Risk factor |
Effect on launch probability |
| Expired core exclusivity |
Increases legal feasibility |
| Limited public litigation |
May reduce launch friction |
| Sterile injectable manufacturing |
Raises technical barriers |
| Small product revenue base |
May reduce generic incentives |
| Hospital price pressure |
Increases substitution risk |
| Established Bracco supply network |
Supports brand retention |
| Macrocyclic preference |
Can weaken demand before generic entry |
A first generic entrant could gain share through low pricing and hospital contracts. The impact would be greatest in tender-driven systems and least in institutions that prioritize continuity, clinical familiarity, or a specific imaging protocol.
A settlement agreement would be commercially important if it delayed entry, restricted an authorized generic, or established a launch date. No widely reported settlement currently defines the U.S. MultiHance market in the way that settlements have shaped major pharmaceutical products.
Which companies are challenging gadobenate’s market position?
Competition comes from manufacturers of alternative MRI contrast agents rather than from a single direct challenger. The principal competitive companies include Bayer, Guerbet, GE HealthCare, and other suppliers of gadolinium products and generic contrast media.
Bayer
Bayer competes through Gadavist, a macrocyclic gadolinium agent with broad global recognition and strong hospital presence. Its positioning benefits from the market shift toward macrocyclic products.
Guerbet
Guerbet competes through Dotarem and other diagnostic imaging products. Dotarem’s macrocyclic profile gives Guerbet a direct advantage in institutions emphasizing macrocyclic agents.
GE HealthCare
GE HealthCare participates in diagnostic imaging contrast media and benefits from its broader relationships with imaging departments, equipment platforms, and hospital procurement organizations.
The competitive landscape is therefore based on product safety profile, supply, price, imaging performance, and portfolio contracting. Brand-level differentiation is weaker than it was during the early MultiHance launch period.
What manufacturing and intellectual-property barriers support MultiHance?
Manufacturing is a more meaningful barrier than patent exclusivity. Gadobenate production requires controlled chelation chemistry, pharmaceutical-grade raw materials, sterile injectable manufacturing, validated filling operations, container closure integrity, and consistent impurity control.
A generic applicant must demonstrate pharmaceutical equivalence, bioequivalence or an acceptable alternative regulatory basis, stability, sterility, and manufacturing compliance. Contrast media also require dependable global supply because imaging departments have limited tolerance for product shortages.
Bracco’s practical defenses include:
- Established manufacturing capacity.
- Regulatory history across multiple jurisdictions.
- Hospital and distributor relationships.
- Existing pharmacovigilance infrastructure.
- Physician familiarity.
- Ability to bundle products within a broader imaging portfolio.
These defenses can preserve branded sales after legal exclusivity ends, but they do not prevent price erosion if several approved competitors enter.
What is the outlook for gadobenate dimeglumine?
The base-case outlook is stable to moderately declining revenue in mature markets, with upside from MRI volume growth and selected liver-imaging demand. Unit volumes may rise while net pricing declines. The product is more likely to remain a profitable portfolio asset than to become a major growth engine.
The highest-risk scenario involves simultaneous macrocyclic substitution and generic entry. That combination could reduce both volume and price. The stronger scenario involves continued supply reliability, limited generic competition, and stable use in liver MRI.
Key Takeaways
- Gadobenate dimeglumine is a mature MRI contrast agent marketed mainly as MultiHance by Bracco.
- U.S. approval began in 2004, with liver imaging added later.
- Original regulatory exclusivity has expired.
- Product-level Bracco revenue is not publicly disclosed.
- Patent protection is less important today than manufacturing, supply, contracting, and brand retention.
- Macrocyclic gadolinium agents are the main strategic competitive threat.
- Generic entry is legally feasible but may be limited by sterile manufacturing requirements and modest product economics.
- The most likely financial trajectory is stable or declining revenue with continued portfolio profitability.
- No major public Paragraph IV litigation or settlement currently defines the product’s commercial outlook.
- The product has no biosimilar risk because it is a small-molecule contrast agent.
FAQs about gadobenate dimeglumine market and patents
Is gadobenate dimeglumine still commercially important?
Yes. It remains an established MRI contrast agent, particularly where clinicians value its imaging performance and liver-imaging indication. Its commercial importance is greater within Bracco’s diagnostic imaging portfolio than as a standalone high-growth pharmaceutical asset.
Is MultiHance a macrocyclic gadolinium agent?
No. Gadobenate dimeglumine is a linear ionic gadolinium chelate. It competes against macrocyclic agents such as gadobutrol, gadoterate meglumine, and gadoteridol.
Can a generic company launch gadobenate dimeglumine?
In principle, yes. The original exclusivity period has expired, but a generic applicant must address any current listed patents, FDA requirements, sterile manufacturing, quality controls, and commercial supply obligations.
Does gadobenate dimeglumine have biosimilar competition?
No. Gadobenate is a small-molecule drug, not a biologic. Competition would arise through generic or other small-molecule regulatory pathways.
What is the biggest long-term threat to MultiHance sales?
The largest structural threat is substitution by macrocyclic gadolinium agents, particularly when hospitals combine safety preferences with competitive tenders and portfolio purchasing.
References
-
U.S. Food and Drug Administration. (2004). MultiHance (gadobenate dimeglumine) injection: Approval history and prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.
-
U.S. Food and Drug Administration. (2018). FDA warns that gadolinium-based contrast agents are retained in the body; requires new class warnings. FDA Drug Safety Communication.
-
European Medicines Agency. (2017). Gadolinium-containing contrast agents: referral outcome. EMA.
-
Bracco S.p.A. (2023). Corporate and financial information. Bracco.
